Glycoengineered type II anti‑CD20 IgG1 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells; its afucosylated Fc increases affinity for Fc-gamma RIIIa, enhancing ADCC (and ADCP), and it induces direct, caspase-independent cell death, leading to B-cell depletion.
YES
DIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages Fc-gamma RIIIa on effector cells to drive potent ADCC/ADCP and it also induces direct, caspase-independent cell death of CD20+ cells (with limited CDC).
Glycoengineered type II anti‑CD20 IgG1 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells; its afucosylated Fc increases affinity for Fc-gamma RIIIa, enhancing ADCC (and ADCP), and it induces direct, caspase-independent cell death, leading to B-cell depletion.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages FcγRIIIa (CD16a) on NK cells/macrophages to trigger ADCC/ADCP, killing CD20+ B cells. CD16a-expressing effector cells are not targeted or killed by the drug.
Glycoengineered type II anti‑CD20 IgG1 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells; its afucosylated Fc increases affinity for Fc-gamma RIIIa, enhancing ADCC (and ADCP), and it induces direct, caspase-independent cell death, leading to B-cell depletion.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages Fcγ receptors on effector cells (e.g., CD16a on NK cells, CD16b on neutrophils) to mediate ADCC/ADCP and also induces direct cell death of CD20+ B cells. CD16b-expressing cells are not targeted or killed.
Individualized intravenous mRNA cancer vaccine encoding patient-specific neoantigens; taken up by dendritic cells to drive antigen presentation and prime/expand tumor-specific CD8/CD4 T cells.
Individualized intravenous mRNA vaccine encoding patient-specific neoantigens; taken up by dendritic cells, translated into neoantigen peptides, and presented on MHC I/II to prime and expand tumor-specific CD8+ and CD4+ T cells, generating cytotoxic and memory responses against neoantigen-expressing tumor cells.
YES
INDIRECT
The mRNA vaccine primes and expands neoantigen-specific T cells; CTLs recognize neoantigen–MHC I on tumor cells and kill them via perforin/granzyme (and Fas–FasL) pathways, with CD4+ T-cell help.
Individualized intravenous mRNA cancer vaccine encoding patient-specific neoantigens; taken up by dendritic cells to drive antigen presentation and prime/expand tumor-specific CD8/CD4 T cells.
Individualized intravenous mRNA vaccine encoding patient-specific neoantigens; taken up by dendritic cells, translated into neoantigen peptides, and presented on MHC I/II to prime and expand tumor-specific CD8+ and CD4+ T cells, generating cytotoxic and memory responses against neoantigen-expressing tumor cells.
YES
INDIRECT
The mRNA vaccine primes neoantigen‑specific CD4+ (MHC II–restricted) and CD8+ T cells via APC presentation; these T cells then recognize the neoantigen peptides on tumor cells and kill them via perforin/granzyme and/or Fas–FasL pathways.